Discovery and lead identification of quinazoline-based BRD4 inhibitors.
Yang, S.M., Urban, D.J., Yoshioka, M., Strovel, J.W., Fletcher, S., Wang, A.Q., Xu, X., Shah, P., Hu, X., Hall, M.D., Jadhav, A., Maloney, D.J.(2018) Bioorg Med Chem Lett 28: 3483-3488
- PubMed: 30268702 
- DOI: https://doi.org/10.1016/j.bmcl.2018.08.039
- Primary Citation of Related Structures:  
6E4A - PubMed Abstract: 
A new series of quinazoline-based analogs as potent bromodomain-containing protein 4 (BRD4) inhibitors is described. The structure-activity relationships on 2- and 4-position of quinazoline ring, and the substitution at 6-position that mimic the acetylated lysine are discussed. A co-crystallized structure of 48 (CN750) with BRD4 (BD1) including key inhibitor-protein interactions is also highlighted. Together with preliminary rodent pharmacokinetic results, a new lead (65, CN427) is identified which is suitable for further lead optimization.
Organizational Affiliation: 
National Center for Advancing Translational Sciences, National Institutes of Health, 9800 Medical Center Drive, Rockville, MD 20850, United States. Electronic address: yangs9@mail.nih.gov.